Vera Therapeutics, Inc. (VERA)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-15

Key Insights

  • The filing indicates that the CEO, Marshall Fordyce, has sold a significant amount of Vera Therapeutics' Class A common stock, totaling over 22,000 shares. This may raise concerns about management's confidence in the company's near-term prospects.
  • The shares were sold pursuant to a 10b5-1 trading plan, suggesting the transactions were pre-planned and not necessarily driven by new information. However, the timing and magnitude of the sales could still be viewed negatively by investors.
  • The CEO still holds a substantial number of shares, both directly and indirectly through a trust and a GRAT, indicating he maintains a significant ownership stake in the company. This may help mitigate concerns about the insider selling.
Filing tone (AI): Negative
View Original Filing →
Insider Trading Filed: 2026-03-25

Key Insights

  • Jane Wright-Mitchell, the Chief Legal Officer of Vera Therapeutics, Inc. (VERA), acquired 42,403 shares of Class A Common Stock through restricted stock units (RSUs), indicating her commitment to the company.
  • Wright-Mitchell also received a stock option to purchase 56,850 shares of Class A Common Stock, further aligning her interests with those of the company and its shareholders.
  • The vesting schedules for both the RSUs and the stock option suggest a long-term focus, with the RSUs vesting over 4 years and the stock option vesting over 9 years, indicating Wright-Mitchell's belief in the company's long-term potential.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Vera Therapeutics, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.